USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Product and Pipeline Analysis of the Global Psoriasis Therapeutics Market
Product and Pipeline Analysis of the Global Psoriasis Therapeutics Market
RELEASE DATE
12-Mar-2014
12-Mar-2014
REGION
Global
Global
Research Code: ND8B-01-00-00-00
SKU: LS00121-GL-MR_16962
$3,950.00
Special Price $2,962.50 save 25 %
In stock
SKU
LS00121-GL-MR_16962
Description
The dermatology space has been transformed with the introduction of biologic therapy for psoriasis, with several additional novel drug classes on the verge of market introduction. This research service provides a comprehensive overview and analysis of marketed and investigational products for the treatment of psoriasis. Information on market background and a global overview and analysis of drug development, detailed product and pipeline analysis by disease severity, drug class and stage of development, and detailed product dashboards for key marketed and late-stage products are also included in the study.
Table of Contents
Executive Summary
Executive Summary (continued)
Methodology and Scope
Introduction
Disease Classification
Epidemiology
Epidemiology (continued)
Efficacy Assessment Tools
Segmentation
Segmentation (continued)
Segmentation (continued)
Competitive Landscape—Mild-to-moderate PS, Products in Development
Competitive Landscape—Moderate-to-severe PS, Marketed Products and Products in Development
Competitive Landscape—Pivotal Phase 3 Trials
Competitive Landscape—Pivotal Phase 3 Trials (continued)
Timeline of Key Events
Comparative Efficacy of Select Marketed and Investigational Drugs
Comparative Efficacy Discussion
Marketed Products Analysis
Marketed Products Analysis (continued)
Marketed Products Analysis (continued)
Marketed Products Analysis (continued)
Marketed Products Analysis (continued)
Pipeline Analysis
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Pipeline Analysis (continued)
Product Dashboard—Enbrel (etanercept)
Product Dashboard—Remicade (infliximab)
Product Dashboard—Humira (adalimumab)
Product Dashboard—Stelara (ustekimunab)
Product Dashboard—Secukinumab (AIN457)
Product Dashboard—Izekizumab (LY2439821)
Product Dashboard—Brodalumab (AMG 827)
Product Dashboard—Apremilast
Product Dashboard—Xeljanz (tofacitinib)
Product Dashboard—Tildrakizumab (MK-3222)
Conclusions and Recommendations
Conclusions and Recommendations (continued)
New Market Opportunities
Companies to Watch
Legal Disclaimer
Comparative Efficacy of Select Marketed and Investigational Drugs
Who is Frost & Sullivan
What Makes Us Unique
TEAM Methodology
Our Global Footprint 40+ Offices
Popular Topics
Immunoglobulin therapies are life-saving medicines that have been in use for more than 60 years. They provide the patient with a variety of antibodies and are often used as a last line of defense in many severe inflammatory diseases. In some conditions, they are life-saving. However, immunoglobulin therapies are expensive. Despite this, global demand for immunoglobulin is growing and the market is expected to foresee increased competition. As of 2015, more than 40 immunoglobulin treatments have been approved, with another 28 in various stages of development. This research service provides an overview of the marketed products and those in the pipeline. The analysis divides these treatments by the communicable and non-communicable diseases that they treat. In addition, key products and companies are profiled.
| No Index | No |
|---|---|
| Podcast | No |
| WIP Number | ND8B-01-00-00-00 |
| Is Prebook | No |